David I. Quinn, MBBS, PhD, of the University of Southern California, gives his expert perspective on the planned survival analysis from a phase III open-label study of pembrolizumab vs paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer. (Abstract 4501)
Jane McNeil Beith, MD, PhD, of Chris O’Brien Lifehouse, discusses long-term study results on a psychological intervention, called “Conquer Fear,” designed to reduce clinical levels of fear of cancer recurrence in breast, colorectal, and melanoma cancer survivors. (Abstract LBA10000)
Arnaud Scherpereel, MD, PhD, of the University Hospital of Lille, discusses in French phase II study findings on second- or third-line nivolumab vs nivolumab plus ipilimumab in malignant pleural mesothelioma patients. (Abstract LBA8507)
Jame Abraham, MD, of the Cleveland Clinic, gives his views on findings on abemaciclib in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer who progressed on endocrine therapy. (Abstract 1000)
Nicholas D. James, MBBS, PhD, of Queen Elizabeth Hospital, discusses study findings on adding abiraterone for men with high-risk prostate cancer starting long-term androgen-deprivation therapy (Abstract LBA5003).
David H. Henry, MD, of Pennsylvania Oncology Hematology Associates, and Ruben A. Mesa, MD, of the Mayo Clinic Cancer Center, discuss phase III study findings on momelotinib vs ruxolitinib in JAK inhibitor–naive patients with myelofibrosis. (Abstract 7000)
